0.659
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DRRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.6701
Offen:
$0.76
24-Stunden-Volumen:
44,618
Relative Volume:
0.67
Marktkapitalisierung:
$18.28M
Einnahmen:
$8.59M
Nettoeinkommen (Verlust:
$-17.07M
KGV:
-1.0803
EPS:
-0.61
Netto-Cashflow:
$-21.90M
1W Leistung:
+11.88%
1M Leistung:
-12.02%
6M Leistung:
-45.54%
1J Leistung:
-38.41%
Durect Corp Stock (DRRX) Company Profile
Firmenname
Durect Corp
Sektor
Telefon
(408) 777-1417
Adresse
10240 BUBB ROAD, CUPERTINO, CA
Vergleichen Sie DRRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
DRRX
Durect Corp
|
0.659 | 18.28M | 8.59M | -17.07M | -21.90M | -0.61 |
![]()
ZTS
Zoetis Inc
|
160.41 | 66.72B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.45 | 48.08B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 47.74B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.48 | 18.49B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
308.07 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-10-30 | Eingeleitet | Chardan Capital Markets | Buy |
2020-10-12 | Eingeleitet | ROTH Capital | Buy |
2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
2020-01-31 | Eingeleitet | B. Riley FBR | Buy |
2019-11-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2019-09-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-03-06 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2017-10-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2017-10-20 | Bestätigt | Laidlaw | Buy |
2017-10-20 | Herabstufung | Stifel | Buy → Hold |
2017-07-12 | Hochstufung | Stifel | Hold → Buy |
2017-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
2016-04-25 | Eingeleitet | Rodman & Renshaw | Buy |
2015-05-01 | Bestätigt | Cantor Fitzgerald | Buy |
2015-05-01 | Bestätigt | Stifel | Buy |
2013-03-25 | Eingeleitet | Stifel | Buy |
2012-11-01 | Herabstufung | C.K. Cooper | Buy → Hold |
2012-08-17 | Eingeleitet | C.K. Cooper | Buy |
2009-06-23 | Eingeleitet | Caris & Company | Buy |
2009-03-26 | Eingeleitet | Wedbush Morgan | Hold |
Alle ansehen
Durect Corp Aktie (DRRX) Neueste Nachrichten
DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com - Defense World
Durect Corp Q1 2025 Earnings: EPS at -$0.13 Misses Estimate, Rev - GuruFocus
DURECT (DRRX) Q1 Revenue Surpasses Estimates, Focuses on Phase 3 Trial Funding | DRRX Stock News - GuruFocus
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Durect Corp stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Durect Corp stock hits 52-week low at $0.69 amid market challenges - Investing.com
Form 8-KCurrent report - ADVFN
DURECT Co. (NASDAQ:DRRX) Sees Large Decline in Short Interest - Defense World
DURECT (NASDAQ:DRRX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.7 amid market challenges - Investing.com Canada
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - MSN
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - MySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
DURECT (DRRX) to Release Quarterly Earnings on Wednesday - Defense World
DURECT Q4 Earnings Preview: Key Financial Results and Strategic Updates Coming March 26 - Stock Titan
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - Simply Wall St
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld Online
Larsucosterol flops on clinical benefit in phase 2b alcohol-associated hepatitis trial - Healio
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
The R&D Dept.: Local patent roundup for 2.26.25 - RichmondBizSense
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Exclusive Healthcare Conference Alert: DURECT CEO Reveals Latest Developments - Stock Titan
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
Finanzdaten der Durect Corp-Aktie (DRRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):